Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773109 · ClinicalTrials.gov registry record · Phase 2
Etirinotecan Pegol (NKTR-102) in NSCLC
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT01773109 is a Phase 2 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 40 participants.
The verdict
NCT01773109, a Phase 2 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This Phase 2 study is designed to characterize the objective response rate (defined as complete response (CR) and partial response (PR)) of Etirinotecan pegol administered to subjects with metastatic and recurrent NSCLC after failure of 2nd line therapy. Up to 37 eligible subjects will receive the investigational drug q3 weeks until they are no longer benefiting.
Interventions
- DRUG Etirinotecan pegol (NKTR-102)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-01 |
| Est. Completion | 2017-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01773109
The ClinicalTrials.gov registry entry for NCT01773109 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etirinotecan pegol (NKTR-102) is the first listed.
NCT01773109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01773109 about?
NCT01773109 is a clinical study titled "Etirinotecan Pegol (NKTR-102) in NSCLC". This Phase 2 study is designed to characterize the objective response rate (defined as complete response (CR) and partial response (PR)) of Etirinotecan pegol administered to subjects with metastatic and recurrent NSCLC after failure of 2nd line therapy. Up to 37 eligible subjects will receive the i...
What is the current status of trial NCT01773109?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2013-01. Estimated completion is 2017-03-15.
What interventions are being tested in trial NCT01773109?
The interventions under investigation include: Etirinotecan pegol (NKTR-102) (DRUG).
Who is sponsoring clinical trial NCT01773109?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.